Daiichi Sankyo Seals Speedier Europe Review For Quizartinib
Executive Summary
The acute myeloid leukemia drug is the lead candidate in the strong oncology pipeline the Japan-headquartered company has assembled over the past couple of years.
You may also be interested in...
Daiichi Taps AnHeart As It Focuses Oncology Push
As part of its strategic pivot towards oncology, Daiichi Sankyo reaches a global out-licensing deal with a little-known US venture for an early-stage asset, which also hints at where its priorities lie.
More Good News For AML As Pfizer And AbbVie/Roche Drugs Get FDA Okay
The options for AML are on the rise after no drugs for decades and the green lights for Daurismo and Venclexta mean that seven therapies for the disease have now been approved by the FDA since 2017.
EU Accelerated Assessment Tracker: Second Half Trumps First By Far
The first half of the year was pretty bleak for companies seeking fast-track review of their products in the EU. There has been much better news in the second half. The Pink Sheet tracks the winners and losers.